Paper803104
Expansion of the growth fraction in multiple myeloma with alkylating agents.
Salmon SE. Blood, 1975. Cited by 108 papers, by iCite.
Cite this record
ConductScience Library. Expansion of the growth fraction in multiple myeloma with alkylating agents. Papers, record 803104. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/803104
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Melphalan | Major topic |
| Multiple Myeloma | Major topic |
| Vincristine | Major topic |
| Adult | |
| Bone Marrow | |
| Cell Count | |
| DNA Replication | |
| Humans | |
| Kinetics | |
| Male | |
| Prednisone |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| CA-14087 | NCI NIH HHS | United States | PubMed | |
| CA-14102 | NCI NIH HHS | United States | PubMed | |
| NCI-C-73-7313 | NCPDCID CDC HHS | United States | PubMed |
Source PubMed
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 108 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 7764456 | Kinetic resistance to anticancer agents. | Cytotechnology | 1993 | https://conductscience.org/library/papers/7764456 | PubMed |
| 7006664 | Treatment comparisons in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults. | Br J Cancer | 1980 | https://conductscience.org/library/papers/7006664 | PubMed |
| 6801866 | Hematologic disorders in the elderly. | West J Med | 1981 | https://conductscience.org/library/papers/6801866 | PubMed |
| 3896288 | Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults. | Br J Cancer | 1985 | https://conductscience.org/library/papers/3896288 | PubMed |
| 2347050 | Timed sequential chemotherapy following ifosfamide-induced kinetic recruitment in refractory ovarian cancer. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2347050 | PubMed |
| 1749301 | Interphase cell death as related to the cell cycle of melphalan-treated human myeloma cells. | Med Oncol Tumor Pharmacother | 1991 | https://conductscience.org/library/papers/1749301 | PubMed |
| 656862 | Progress in myeloma at last. | Br Med J | 1978 | https://conductscience.org/library/papers/656862 | PubMed |
| 302265 | Primary bioassay of human myeloma stem cells. | J Clin Invest | 1977 | https://conductscience.org/library/papers/302265 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/803104
GET https://conductscience.org/api/papers/v1/803104/authors